4,120,053 Shares in Maze Therapeutics, Inc. $MAZE Acquired by ARCH Venture Management LLC

ARCH Venture Management LLC purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 4,120,053 shares of the company's stock, valued at approximately $122,983,582. Maze Therapeutics makes up approximately 0.0% of ARCH Venture Management LLC's portfolio, making the stock its 7th largest position. ARCH Venture Management LLC owned approximately 7.42% of Maze Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. TRV GP IV LLC acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at approximately $133,502,907. BlackRock Inc. acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at approximately $104,525,000. Janus Henderson Group PLC raised its position in shares of Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company's stock valued at $130,197,000 after purchasing an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company's stock valued at $70,307,000 after purchasing an additional 362,060 shares in the last quarter. Finally, Alphabet Inc. acquired a new position in shares of Maze Therapeutics in the 2nd quarter valued at approximately $41,435,000.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on MAZE. BTIG Research reaffirmed a "buy" rating and issued a $46.00 target price on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Wall Street Zen lowered Maze Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, TD Cowen raised Maze Therapeutics to a "strong-buy" rating in a research report on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics presently has a consensus rating of "Buy" and an average target price of $66.00.

Maze Therapeutics Price Performance

Shares of NASDAQ MAZE opened at $27.44 on Friday. Maze Therapeutics, Inc. has a twelve month low of $13.89 and a twelve month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -10.89 and a beta of 2.21. The business has a 50 day simple moving average of $28.74 and a 200-day simple moving average of $31.90.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). As a group, equities research analysts expect that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Atul Dandekar sold 7,500 shares of the company's stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the transaction, the insider directly owned 26,250 shares in the company, valued at $717,675. This represents a 22.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 16,142 shares of the company's stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total value of $445,680.62. Following the transaction, the chief marketing officer owned 16,142 shares of the company's stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 108,110 shares of company stock worth $3,057,531 in the last three months. 5.30% of the stock is owned by insiders.

About Maze Therapeutics

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.